Therapeutic Approaches Targeting Prostate Cancer Progression Using Novel Voltage-Gated Ion Channel Blockers

Clinical Prostate Cancer

Volumn 2, Issue 3, 2003, Pages 181-187

  Sikes, Robert A ^a   Walls, Alison M ^a   Brennen, W Nathaniel ^a   Anderson, James D ^b   Choudhury Mukherjee, Indrani ^b   Schenck, Hilary A ^b   Brown, Milton L ^b  

^a UNIVERSITY OF DELAWARE   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Calcium ions; Invasive disease; Proliferation; Sodium channel blockade

Indexed keywords

AJMALINE; AMIDE; ANILIDE; ARACHIDONIC ACID; BATRACHOTOXIN; CALCIUM CHANNEL BLOCKING AGENT; CIGUATOXIN; CONOTOXIN; DOXORUBICIN; GRAYANOTOXIN; HS I 35; HYDANTOIN DERIVATIVE; ICM I 136; ICM I 55 W; JDA I 73; JDA II 105; JDA II 145; LIDOCAINE; OLEIC ACID; PHENYTOIN; PURINERGIC RECEPTOR BLOCKING AGENT; QUINIDINE; SCORPION VENOM; SODIUM CHANNEL BLOCKING AGENT; SPARTEINE; TETRODOTOXIN; TH 1177; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL; VINBLASTINE; VOLTAGE GATED CALCIUM CHANNEL; VOLTAGE GATED SODIUM CHANNEL;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CELL MIGRATION; CELL STRUCTURE; CORRELATION ANALYSIS; DRUG BINDING SITE; DRUG DESIGN; DRUG EFFECT; DRUG MECHANISM; DRUG SENSITIVITY; EARLY DIAGNOSIS; HUMAN; IN VITRO STUDY; INNERVATION; METASTASIS; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; QUALITY OF LIFE; TUMOR XENOGRAFT;

EID: 0346875862     PISSN: 15400352     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2003.n.028     Document Type: Article

References (73)

1. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003; CA Cancer J Clin 2003; 53:5-26.
2. Colanzi, P, Santinelli A, Mazzucchelli R, et al. Changes in the normal-looking epithelium in prostates with PIN or cancer. Adv Clin Pathol 1999; 3:129-134.
3. Carlin BI, Andriole GL. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer 2000; 88(suppl 12):2989-2994.
4. Sadar MD, Gleave ME. Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells. Cancer Res 2000; 60:5825-5831.
5. Gleave ME, Sato N, Sadar M, et al. Butyrate analogue, isobutyramide, inhibits tumor growth and time to androgen-independent progression in the human prostate LNCaP tumor model. J Cell Biochem 1998; 69:271-281.
6. Walls R, Thibault A, Liu L, et al. The differentiating agent phenylacetate increases prostate-specific antigen production by prostate cancer cells. Prostate 1996; 29:177-182.
7. Fong CJ, Sutkowski DM, Braun EJ, et al. Effect of retinoic acid on the proliferation and secretory activity of androgen-responsive prostatic carcinoma cells. J Urol 1993; 149:1190-1194.
8. Zhao XY, Peehl DM, Navone NM, et al. 1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms. Endocrinology 2000; 141:2548-2556.
9. Zhao XY, Ly LH, Peehl DM, et al. Induction of androgen receptor by 1alpha,25-dihydroxyvitamin D3 and 9-cis retinoic acid in LNCaP human prostate cancer cells. Endocrinology 1999; 140:1205-1212.
10. Zhao XY, Ly LH, Peehl DM, et al. 1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent. Endocrinology 1997; 138:3290-3298.
11. Hobisch A, Eder IE, Putz T, et al. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res 1998; 58:4640-4645.
12. McVary KT, McKenna KE, Lee C. Prostate innervation. Prostate 1998; 8(suppl):2-13.
13. Jen PY, Dixon JS, Gearhart JP, et al. Nitric oxide synthase and tyrosine hydroxylase are colocalized in nerves supplying the postnatal human male genitourinary organs. J Urol 1996; 155:1117-1121.
14. Pflug BR, Dionne C, Kaplan DR, et al. Expression of a Trk high affinity nerve growth factor receptor in the human prostate. Endocrinology 1995; 136:262-268.
15. Paul A, Habib F. Low-affinity nerve growth factor receptors (p75LNGFR) in human prostate tissue: stromal localisation. Urol Res 1998; 26:111-116.
16. Paul AB, Grant ES, Habib FK. The expression and localisation of beta-nerve growth factor (beta-NGF) in benign and malignant human prostate tissue: relationship to neuroendocrine differentiation. Br J Cancer 1996; 74:1990-1996.
17. Perez M, Regan T, Pflug B, et al. Loss of low-affinity nerve growth factor receptor during malignant transformation of the human prostate. Prostate 1997; 30:274-279.
18. Guate JL, Fernandez N, Lanzas JM, et al. Expression of p75(LNGFR) and Trk neurotrophin receptors in normal and neoplastic human prostate. BJU Int 1999; 84:495-502.
19. Dalal R, Djakiew D. Molecular characterization of neurotrophin expression and the corresponding tropomyosin receptor kinases (trks) in epithelial and stromal cells of the human prostate. Mol Cell Endocrinol 1997; 134:15-22.
20. Wang JM, McKenna KE, McVary KT, et al. Requirement of innervation for maintenance of structural and functional integrity in the rat prostate. Biol Reprod 1991; 44:1171-1176.
21. Guthrie PD, Freeman MR, Liao ST et al. Regulation of gene expression in rat prostate by androgen and beta-adrenergic receptor pathways. Mol Endocrinol 1990; 4:1343-1353.
22. McVary KT, Razzaq A, Lee C, et al. Growth of the rat prostate gland is facilitated by the autonomic nervous system. Biol Reprod 1994; 51:99-107.
23. Golomb E, Kruglikova A, Dvir D, et al. Induction of atypical prostatic hyperplasia in rats by sympathomimetic stimulation. Prostate 1998; 34:214-221.
24. Bonkhoff H. Neuroendocrine cells in benign and malignant prostate tissue: morphogenesis, proliferation, and androgen receptor status. Prostate 1998; 8(suppl):18-22.
25. di Sant'Agnese PA. Neuroendocrine differentiation in prostatic carcinoma: an update. Prostate 1998; 8(suppl):74-79.
26. Theodorescu D, Broder SR, Boyd JC, et al. Cathepsin D and chromogranin A as predictors of long-term disease specific survival after radical prostatectomy for localized carcinoma of the prostate. Cancer 1997; 80:2109-2119.
27. Fixemer T, Remberger K, Bonkhoff H. Apoptosis resistance of neuroendocrine phenotypes in prostatic adenocarcinoma. Prostate 2002; 53:118-123.
28. Cox ME, Deeble PD, Lakhani S, et al. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression. Cancer Res 1999; 59:3821-3830.
29. Seethalakshmi L, Mitra SP, Dobner PR, et al. Neurotensin receptor expression in prostate cancer cell line and growth effect of NT at physiological concentrations. Prostate 1997; 31:183-192.
30. Burchardt T, Burchardt M, Chen MW, et al. Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo. J Urol 1999; 162:1800-1805.
31. Jongsma J, Oomen MH, Noordzij MA, et al. Androgen deprivation of the PC-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiation. Cancer Res 2000; 60:741-748.
32. Najbat-Kaszkiel AT, Di Julio JL, Li CG, et al. Characterisation of excitatory and inhibitory transmitter systems in prostate glands of rats, guinea pigs, rabbits and pigs. Eur J Pharmacol 1997; 337:251-258.
33. Brodie C, Sampson SR. Nerve growth factor and fibroblast growth factor influence post-fusion expression of Na-channels in cultured rat skeletal muscle. J Cell Physiol 1990; 144:492-497.
34. Goldin AL, Barchi RL, Caldwell JH, et al. Nomenclature of voltage-gated sodium channels. Neuron 2000; 28:365-368.
35. Batra S, Popper LD, Hartley-Asp B. Effect of calcium and calcium antagonists on 45Ca influx and cellular growth of human prostatic tumor cells. Prostate 1991; 19:299-311.
36. Skryma RN, Prevarskaya NB, Dufy-Barbe L, et al. Potassium conductance in the androgen-sensitive prostate cancer cell line, LNCaP: involvement in cell proliferation. Prostate 1997; 33:112-122.
37. Diss JK, Archer SN, Hirano J, et al. Expression profiles of voltage-gated Na(+) channel alpha-subunit genes in rat and human prostate cancer cell lines. Prostate 2001; 48:165-178.
38. Diss JK, Stewart D, Fraser SP, et al. Expression of skeletal muscle-type voltage-gated Na+ channel in rat and human prostate cancer cell lines. FEBS Lett 1998; 427:5-10.
39. Abdul M, Hoosein N. Inhibition by anticonvulsants of prostate-specific antigen and interleukin-6 secretion by human prostate cancer cells. Anticancer Res 2001; 21:2045-2048.
40. Abdul M, Hoosein N. Voltage-gated sodium ion channels in prostate cancer: expression and activity. Anticancer Res 2002; 22:1727-1730.
41. Fraser SP, Ding Y, Liu A, et al. Tetrodotoxin suppresses morphological enhancement of the metastatic MAT-LyLu rat prostate cancer cell line. Cell Tissue Res 1999; 295:505-512.
42. Fraser SP, Grimes JA, Djamgoz MB. Effects of voltage-gated ion channel modulators on rat prostatic cancer cell proliferation: comparison of strongly and weakly metastatic cell lines. Prostate 2000; 44:61-76.
43. Djamgoz MBA, Mycielska M, Madeja Z, et al. Directional movement of rat prostate cancer cells in direct-current electric field: involvement of voltage gated Na+ channel activity. J Cell Sci 2001; 114:2697-2705.
44. Smith P, Rhodes NP, Shortland AP, et al. Sodium channel protein expression enhances the invasiveness of rat and human prostate cancer cells. FEBS Lett 1998; 423:19-24.
45. + entry. Cancer Res 2000; 60:1002-1008.
46. David-Beabes GL, Overman MJ, Petrofski JA, et al. Doxorubicin-resistant variants of human prostate cancer cell lines DU 145, PC-3, PPC-1, and TSU-PR1: characterization of biochemical determinants of antineoplastic drug sensitivity. Int J Oncol 2000; 17:1077-1086.
47. Theyer G, Schirmbock M, Thalhammer T, et al. Role of the MDR-1-encoded multiple drug resistance phenotype in prostate cancer cell lines. J Urol 1993; 150:1544-1547.
48. Batra S, Karlsson R, Witt L. Potentiation by estramustine of the cytotoxic effect of vinblastine and doxorubicin in prostatic tumor cells. Int J Cancer 1996; 68:644-649.
49. Laniado ME, Lalani EN, Fraser SP, et al. Expression and functional analysis of voltage-activated Na+ channels in human prostate cancer cell iines lines and their contribution to invasion in vitro. Am J Pathol 1997; 150:1213-1221.
50. Grimes JA, Fraser SP, Stephens GJ, et al. Differential expression of voltage-activated Na+ currents in two prostatic tumour cell lines: contribution to invasiveness in vitro. FEBS Lett 1995; 369:290-294.
51. Grimes JA, Djamgoz MB. Electrophysiological characterization of voltage-gated Na+ current expressed in the highly metastatic Mat-LyLu cell line of rat prostate cancer. J Cell Physiol 1998; 175:50-58.
52. Sretavan DW, Shatz CJ, Stryker MP. Modification of retinal ganglion cell axon morphology by prenatal infusion of tetrodocoxin. Nature 1988; 336:468-471.
53. Mattei C, Dechraoui MY, Molgo J, et al. Neurotoxins targetting receptor site 5 of voltage-dependent sodium channels increase the nodal volume of myelinated axons. J Neurosci Res 1999; 55:666-673.
54. Matsutani S, Yamamoto N. Neuronal regulation of astrocyte morphology in vitro is mediated by GABAergic signaling. Glia 1997; 20:1-9.
55. Hobisch A, Rogatsch H, Hittmair A, et al. Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue. J Pathol 2000; 191:239-244.
56. Smith PC, Hobisch A, Lin DL, et al. Interleukin-6 and prostate cancer progression. Cytokine Growth Factor Rev 2001; 12:33-40.
57. Hobisch A, Ramoner R, Fuchs D, et al. Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype. Clin Cancer Res 2001; 7:2941-2948.
58. Yanagawa Y, Abe T, Satake M, et al. A novel sodium channel inhibitor from Conus geographus: purification, structure, and pharmacological properties. Biochemistry 1988; 27:6256-6262.
59. Bendahhou S, Cummins TR, Potts JF, et al. Serine-1321-independent regulation of the mu 1 adult skeletal muscle Na+ channel by protein kinase C. Proc Natl Acad Sci U S A 1995; 92:12003-12007.
60. Ohizumi Y, Nakamura H, Kobayashi J, et al. Specific inhibition of [3H] saxitoxin binding to skeletal muscle sodium channels by geographutoxin II, a polypeptide channel blocker. J Biol Chem 1986; 261:6149-6152.
61. Bendahhou S, Cummins TR, Agnew WR. Mechanism of modulation of the voltage-gated skeletal and cardiac muscle sodium channels by fatty acids. Am J Physiol 1997; 272:C592-C600.
62. Wieland SJ, Fletcher JE, Gong QH. Differential modulation of a sodium conductance in skeletal muscle by intracellular and extracellular fatty acids. Am J Physiol 1992; 263:C308-C312.
63. Wang DW, Nie L, George AL Jr, et al. Distinct local anesthetic affinities in Na+ channel subtypes. Biophys J 1996; 70:1700-1708.
64. Le Treut T, Boucher JL, Jover E, et al. Localization of voltage-sensitive sodium channels on the extrasynaptic membrane surface of mouse skeletal muscle by autoradiography of scorpion toxin binding sites. J Neurocytol 1990; 19:408-420.
65. Garber SS, Miller C. Single Na+ channels activated by veratridine and batrachotoxin. J Gen Physiol 1987; 89:459-480.
66. Albuquerque EX, Warnick JE. The pharmacology of batrachotoxin. IV: interaction with tetrodotoxin on innervated and chronically denervated rat skeletal muscle. J Pharmacol Exp Ther 1972; 180:683-697.
67. Bidard JN, Vijverberg HP, Frelin C, et al. Ciguatoxin is a novel type of Na+ channel toxin. J Biol Chem 1984; 259:8353-8357.
68. Korper S, Wink M, Fink RH. Differential effects of alkaloids on sodium currents of isolated single skeletal muscle fibers. FEBS Lett 1998; 436:251-255.
69. Masutani T, Seyama I, Narahashi T, et al. Structure-activity relationship for grayanotoxin derivatives in frog skeletal muscle. J Pharmacol Exp Ther 1981; 217:812-819.
70. Brouillette WJ, Jestkov VP, Brown ML, et al. Bicyclic hydantoins with a bridgehead nitrogen. Comparison of anticonvulsant activities with binding to the neuronal voltage-dependent sodium channel. J Med Chem 1994; 37:3289-3293.
71. Brown ML, Brown GB, Brouillette WJ. Effects of log P and phenyl ring conformation on the binding of 5-phenylhydantoins to the voltage-dependent sodium channel. J Med Chem 1997; 40:602-607.
72. Brown ML, Zha CC, Van Dyke CC, et al. Comparative molecular field analysis of hydantoin binding to the neuronal voltage-dependent sodium channel. J Med Chem 1999; 42:1537-1545.
73. Anderson JD, Hansen TP, Lenkowski, et al. Voltage-gated sodium channel blockers as cytostatic inhibitors of the androgen-independent prostate cancer cell line PC-3. Mol Cancer Ther 2003; 42:1149-1154.